Eyepoint Pharmaceuticals’ (EYPT) “Neutral” Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. reaffirmed their neutral rating on shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) in a research report released on Monday,Benzinga reports.

A number of other analysts have also commented on the company. HC Wainwright cut their price target on Eyepoint Pharmaceuticals from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Cantor Fitzgerald lowered Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Monday. Stifel Nicolaus started coverage on Eyepoint Pharmaceuticals in a research note on Thursday, July 16th. They issued a “buy” rating and a $40.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Friday, July 17th. Finally, Chardan Capital reaffirmed a “neutral” rating and set a $5.00 price target (down from $65.00) on shares of Eyepoint Pharmaceuticals in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Eyepoint Pharmaceuticals has an average rating of “Hold” and a consensus target price of $28.11.

Eyepoint Pharmaceuticals Trading Up 15.2%

EYPT opened at $6.30 on Monday. The stock has a market capitalization of $543.12 million, a P/E ratio of -1.68 and a beta of 1.76. Eyepoint Pharmaceuticals has a 12 month low of $3.95 and a 12 month high of $19.11. The firm’s fifty day simple moving average is $12.85 and its 200 day simple moving average is $13.49.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). The company had revenue of $0.51 million during the quarter, compared to analyst estimates of $0.45 million. Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. On average, equities research analysts predict that Eyepoint Pharmaceuticals will post -3.6 EPS for the current fiscal year.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

A number of large investors have recently modified their holdings of EYPT. Rhumbline Advisers grew its holdings in shares of Eyepoint Pharmaceuticals by 11.0% in the 2nd quarter. Rhumbline Advisers now owns 96,280 shares of the company’s stock valued at $906,000 after acquiring an additional 9,548 shares in the last quarter. American Century Companies Inc. increased its position in shares of Eyepoint Pharmaceuticals by 57.8% in the second quarter. American Century Companies Inc. now owns 67,612 shares of the company’s stock valued at $636,000 after acquiring an additional 24,752 shares during the last quarter. Invesco Ltd. raised its holdings in Eyepoint Pharmaceuticals by 199.8% during the second quarter. Invesco Ltd. now owns 128,772 shares of the company’s stock worth $1,212,000 after acquiring an additional 85,824 shares in the last quarter. Raymond James Financial Inc. raised its holdings in Eyepoint Pharmaceuticals by 11.0% during the second quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock worth $112,000 after acquiring an additional 1,177 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its holdings in Eyepoint Pharmaceuticals by 9.7% during the second quarter. Adage Capital Partners GP L.L.C. now owns 6,800,000 shares of the company’s stock worth $63,988,000 after acquiring an additional 600,000 shares in the last quarter. 99.41% of the stock is currently owned by institutional investors and hedge funds.

Key Eyepoint Pharmaceuticals News

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: EyePoint said the primary-endpoint miss was largely attributable to nine patients—approximately 4% of the study population—who experienced vision loss unrelated to wet AMD. The company also pointed to favorable secondary endpoints, reduced treatment burden and durable disease control, which could preserve the broader DURAVYU investment case. EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown
• Positive Sentiment: Upcoming LUCIA Phase 3 data, expected in the fourth quarter of 2026, is now a major catalyst. A positive result could help revive confidence in DURAVYU and partially offset the LUGANO failure.
• Positive Sentiment: Citigroup maintained a buy rating while reducing its price target to $17, implying substantial potential upside if the remaining clinical program succeeds.
• Neutral Sentiment: Unusually active options trading included the purchase of about 3,011 call contracts, above average volume. This may reflect speculative positioning around the stock’s volatility and upcoming clinical catalysts rather than a fundamental improvement.
• Negative Sentiment: The LUGANO trial’s failure to achieve its primary endpoint sharply weakened the clinical and regulatory case for DURAVYU in wet AMD. Analysts have questioned whether the secondary results can compensate for the failed head-to-head outcome. EYPT Stock Plunges After Duravyu Misses Phase III Eye Disease Goal
• Negative Sentiment: Royal Bank of Canada downgraded EyePoint to hold and Chardan Capital cut its rating to neutral; both cited $5 price targets. Cantor Fitzgerald also moved to neutral, while Jefferies lowered its expectations. Chardan, JPMorgan and HC Wainwright otherwise maintained neutral-type views.
• Negative Sentiment: The stock reached a new 12-month low as investors reassessed EyePoint’s valuation, execution risk and dependence on future clinical data. EyePoint Hits New 12-Month Low After Analyst Downgrade

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.